:: infobox .infobox-gene Symbol: ATG12 Full Name: Autophagy Related 12 Chromosomal Location: 5q21.2 NCBI Gene ID: 9459 ^{1(2000)2000 · PMID 10654936Open reference} OMIM: 609548 ^{2(2000)2000 · PMID 10785574Open reference} Ensembl ID: ENSG00000181458 ^{3(1999)1999 · PMID 10449416Open reference} UniProt: O95166 ^{4(2007)2007 · PMID 17597759Open reference} Proteins: ATG12 Protein ^{5(2000)2000 · PMID 10702213Open reference} Associated Diseases: Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, ALS ^{6(2003)2003 · PMID 14672461Open reference} :: ^{7(2011)2011 · PMID 22093475Open reference}

ATG12 — Autophagy Related 12

Pathway Diagram

flowchart TD
    ATG12["ATG12"]
    style ATG12 fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0
    Als["Als"]
    ATG12 -->|"activates"| Als
    Autophagy["Autophagy"]
    ATG12 -->|"activates"| Autophagy
    ATG12 -->|"interacts with"| Autophagy
    Neurodegeneration["Neurodegeneration"]
    ATG12 -->|"activates"| Neurodegeneration
    Cancer["Cancer"]
    ATG12 -->|"activates"| Cancer
    MTOR["MTOR"]
    ATG12 -->|"activates"| MTOR
    Mtor["Mtor"]
    ATG12 -->|"activates"| Mtor
    AUTOPHAGY["AUTOPHAGY"]
    ATG12 -->|"activates"| AUTOPHAGY
    SQSTM1["SQSTM1"]
    SQSTM1 -->|"participates in"| ATG12
    P62["P62"]
    P62 -->|"activates"| ATG12
    ATG["ATG"]
    ATG -->|"interacts with"| ATG12
    LC3["LC3"]
    LC3 -->|"interacts with"| ATG12
    ATG5["ATG5"]
    ATG5 -->|"activates"| ATG12
    AUTOPHAGY -->|"activates"| ATG12
    AUTOPHAGY -->|"interacts with"| ATG12
    GENES["GENES"]
    GENES -->|"activates"| ATG12
    style Als fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style Autophagy fill:#5d4400,stroke:#4fc3f7,color:#e0e0e0
    style Neurodegeneration fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style Cancer fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style MTOR fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
    style Mtor fill:#5d4400,stroke:#4fc3f7,color:#e0e0e0
    style AUTOPHAGY fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
    style SQSTM1 fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
    style P62 fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
    style ATG fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
    style LC3 fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
    style ATG5 fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
    style GENES fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0

Introduction

Atg12 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. ^{8(2010)2010 · PMID 20224642Open reference}

Overview

ATG12 (Autophagy Related 12) is a ubiquitin-like protein that plays an essential role in the autophagy pathway, the cellular process responsible for degrading and recycling cytoplasmic components, including misfolded proteins and damaged organelles [1]. Located on chromosome 5q21.2, ATG12 encodes a 140-amino acid protein that undergoes covalent conjugation with ATG5 to form the ATG12-ATG5 conjugate, a critical component of the autophagosome formation machinery [2]. This gene is essential for cellular homeostasis, and its dysfunction is strongly implicated in neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS) [3][4]. ^{9(2011)2011 · PMID 21423150Open reference}

Molecular Function

Ubiquitin-Like Conjugation System

ATG12 is part of the ubiquitin-like protein family involved in autophagy: ^{10(2011)2011 · PMID 21200839Open reference}

1. ATG12 activation: The ATG12 precursor is cleaved by ATG4 protease to expose a C-terminal glycine residue [5].

2. E1 enzyme (ATG7): Activated ATG12 is transferred to ATG7, the E1-like activating enzyme [6].

3. E2 enzyme (ATG10): ATG12 is then transferred to ATG10, the E2-like conjugating enzyme [7].

4. E3-like complex: The ATG12-ATG5 conjugate associates with ATG16L1 to form the ATG16L1 complex, which functions as the E3-like enzyme for LC3 lipidation [8].

ATG12-ATG5 Complex Functions

The ATG12-ATG5 conjugate serves critical functions: ^{2(2000)2000 · PMID 10785574Open reference}0

• LC3 lipidation: Facilitates conversion of LC3-I to LC3-II (phosphatidylethanolamine-conjugated form) [9].

• Phagophore expansion: Promotes expansion and closure of the isolation membrane to form autophagosomes [10].

• Selective autophagy: Works with autophagy receptors (p62, NBR1, OPTN) for selective cargo recognition [11].

• Non-canonical functions: ATG12-ATG5 conjugate can function independently in apoptosis regulation and immune signaling [12].

Comparison with Other ATG Proteins

Expression and Regulation

Tissue Expression

ATG12 is ubiquitously expressed with high levels in: ^{2(2000)2000 · PMID 10785574Open reference}1

• Brain: Cerebral cortex, hippocampus (particularly CA3 pyramidal neurons), cerebellum Purkinje cells

• Liver: Hepatocytes for basal autophagy

• Heart: Cardiomyocytes for protein quality control

• Skeletal muscle: Muscle fibers

Cellular Localization

• Cytoplasmic: Primarily cytosolic distribution

• Autophagosomal membrane: Transient association during autophagosome formation

• Mitochondrial: Under certain stress conditions [13]

Regulation

ATG12 expression is regulated by: ^{2(2000)2000 · PMID 10785574Open reference}2

• Transcriptional: TFEB and TFE3 (transcription factors) activate ATG12 during starvation [14].

• Post-translational: Phosphorylation by ULK1 complex modulates ATG12-ATG5 complex formation [15].

• Feedback loops: Autophagy inhibitors can regulate ATG12 expression in disease states [16].

Role in Neurodegenerative Diseases

Alzheimer’s Disease

In Alzheimer’s disease, ATG12-mediated autophagy is critically impaired [17]: ^{2(2000)2000 · PMID 10785574Open reference}3

• Autophagy-lysosomal dysfunction: AD brains show accumulation of autophagic vesicles, reflecting impaired ATG12-dependent autophagosome formation or maturation [18].

• Amyloid-beta toxicity: Aβ oligomers disrupt ATG12-ATG5 complex function, reducing clearance of Aβ aggregates [19].

• Tau pathology: Impaired autophagy contributes to accumulation of hyperphosphorylated tau [20].

• Neuronal survival: ATG12 deficiency in neurons exacerbates Aβ-induced cell death [21].

Parkinson’s Disease

ATG12 is crucial for PD-relevant processes [22]: ^{2(2000)2000 · PMID 10785574Open reference}4

• Mitophagy: ATG12-ATG5 complex is required for PINK1/Parkin-mediated mitophagy of damaged mitochondria [23].

• Alpha-synuclein clearance: ATG12-dependent autophagy clears alpha-synuclein aggregates [24].

• Dopaminergic neuron vulnerability: ATG12 deficiency accelerates loss of dopaminergic neurons in substantia nigra [25].

Huntington’s Disease

Mutant huntingtin protein impairs ATG12 function [26]: ^{2(2000)2000 · PMID 10785574Open reference}5

• Aggregate clearance: Reduced ATG12-ATG5 activity impairs clearance of mutant huntingtin aggregates [27].

• Cargo recognition: Disrupted interaction with autophagy receptors reduces selective autophagy [28].

• Therapeutic target: Enhancing ATG12-mediated autophagy reduces mutant huntingtin toxicity [29].

Amyotrophic Lateral Sclerosis

In ALS, ATG12 dysfunction contributes to disease progression [30]: ^{2(2000)2000 · PMID 10785574Open reference}6

• Stress granules: ATG12 required for clearance of stress granules containing mutant SOD1 and TDP-43 [31].

• Motor neuron degeneration: ATG12 deficiency in motor neurons promotes aggregation of misfolded proteins [32].

• RNA toxicity: Impaired autophagy leads to accumulation of toxic RNA-protein aggregates [33].

Therapeutic Implications

Autophagy Enhancement Strategies

1. Small molecule inducers:

   • Rapamycin: mTOR inhibition enhances ATG12-mediated autophagy [34].

   • Trehalose: TFEB activation increases ATG12 expression [35].

   • Carbamazepine: Promotes autophagy through TFEB [36].

2. Gene therapy:

   • AAV-mediated ATG12 overexpression in neurons [37].

   • CRISPR activation of ATG12 promoter [38].

3. Combination approaches:

   • Autophagy enhancement with抗氧化剂 [39].

   • Synergistic effects with mitochondrial protectants [40].

Therapeutic Targeting

Genetics

Common Variants

• ATG12 promoter polymorphisms associated with AD risk in some populations [41].

• rs10514210 variant linked to Parkinson’s disease susceptibility [42].

Rare Variants

• Loss-of-function variants cause embryonic lethality in mice [43].

• Missense variants identified in patients with early-onset neurodegeneration [44].

Animal Models

Key models for studying ATG12: ^{2(2000)2000 · PMID 10785574Open reference}7

• Atg12 knockout mice: Embryonic lethal, severe defects in autophagy [45].

• Conditional neuronal KO: Neurodegeneration and protein aggregate accumulation [46].

• Transgenic ATG12 mice: Enhanced autophagy and neuroprotection [47].

--- ^{2(2000)2000 · PMID 10785574Open reference}8

Background

The study of Atg12 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. ^{2(2000)2000 · PMID 10785574Open reference}9

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. ^{3(1999)1999 · PMID 10449416Open reference}0

Additional evidence sources: ^{3(1999)1999 · PMID 10449416Open reference}1 ^{3(1999)1999 · PMID 10449416Open reference}2 ^{3(1999)1999 · PMID 10449416Open reference}3 ^{3(1999)1999 · PMID 10449416Open reference}4 ^{3(1999)1999 · PMID 10449416Open reference}5 ^{3(1999)1999 · PMID 10449416Open reference}6 ^{3(1999)1999 · PMID 10449416Open reference}7 ^{3(1999)1999 · PMID 10449416Open reference}8 ^{3(1999)1999 · PMID 10449416Open reference}9

External Links